市場調查報告書
商品編碼
1466639
轉染試劑和設備市場:按產品、方法、應用和最終用戶分類 - 全球預測 2024-2030Transfection Reagents & Equipment Market by Product (Equipment, Reagents), Method (Biochemical Methods, Physical Methods, Viral Methods), Application, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年轉染試劑和設備市場規模為24.8億美元,2024年達27.9億美元,預計2030年將達到57.6億美元,複合年成長率為12.76%。
轉染試劑和設備在分子和細胞生物學領域至關重要,有助於將核酸引入細胞。這個過程對於遺傳學、蛋白質生產和治療藥物開發的研究和開發至關重要。在生技藥品生產成長、合成基因需求增加以及細胞研究進步的推動下,全球轉染試劑和設備市場正在擴大。生物治療研究活動的活性化以及生物技術和製藥研發投資的增加正在推動市場成長。基因治療領域的不斷擴大和新疫苗的開發正在增加轉染試劑和設備的使用。轉染試劑和先進設備的高成本以及取決於細胞類型的轉染效率和活力的某些限制阻礙了市場成長。更有效率、細胞毒性更低的轉染方法的技術進步以及能夠有效轉染多種細胞類型的新型、毒性更低的轉染試劑的新興市場的開拓預計將創造市場成長機會。
主要市場統計 | |
---|---|
基準年[2023] | 24.8億美元 |
預測年份 [2024] | 27.9億美元 |
預測年份 [2030] | 57.6億美元 |
複合年成長率(%) | 12.76% |
擴大轉染試劑的使用,以促進和增強產品遺傳物質的傳遞
轉染設備在將遺傳物質引入細胞中起著至關重要的作用。此部分通常包括電穿孔器、反應器和其他物理或機械系統,旨在促進核酸有效且受控地引入細胞中。試劑是轉染過程中使用的化學物質或製劑,可促進或增強遺傳物質引入細胞。常見類型包括脂質載體、磷酸鈣載體和病毒載體,每種載體都根據轉染標靶具有不同的益處。不同的實驗設定需要特定類型的設備。電穿孔系統適用於難轉染細胞株和原代細胞的高效轉染,反應器有利於治療藥物生產的大規模轉染。另一方面,磷酸鈣在高通量應用中轉染貼壁細胞具有成本效益。
最終用戶:製藥和生物技術公司的轉染試劑和設備在疫苗和基因療法的開發中具有很大的潛力。
學術和研究機構主要致力於推進各領域的科學研究,包括遺傳學、分子生物學和生物化學。對於這些研究機構來說,轉染試劑和設備對於實驗和研究目的至關重要,尤其是基因表現研究、克隆和蛋白質生產。此類實驗室通常更喜歡經濟高效、可靠且易於使用的解決方案,這些解決方案可以在不影響細胞活力的情況下實現高轉染率。安全性和可重複性也是重要的考慮因素。對於製藥和生物技術公司來說,轉染技術對於藥物發現、治療研究以及疫苗和基因療法開發至關重要。這些公司優先考慮高吞吐量能力、擴充性和準確性。我們專注於加快研發進程,並為成功的商業性應用取得一致且可重複的結果。臨床試驗中的監管合規性和擴充性是更重要的因素。
區域洞察
在美洲,生物技術和製藥領域的研發受到高度重視,對轉染試劑和設備的需求不斷成長。這些地區的客戶優先考慮品質和效率,並需要最新的高通量轉染技術來加速藥物發現和基因研究方法。對個人化醫療和基因治療計劃的投資也在增加,增加了對根據消費者需求量身定做的醫療保健解決方案的需求。歐盟 (EU) 國家因其在基因研究方面的監管領導力和嚴格的轉染實驗品質標準而脫穎而出。這導致學術機構和生技產業之間的合作加強,創造了促進創新轉染技術發展的市場環境。在中東和非洲,人們對轉染技術的興趣日益濃厚,這主要是由於醫療保健和教育領域的投資增加。包括中國、日本和印度在內的亞太地區是一個由市場動態的市場,受到生物技術研究的巨額投資、蓬勃發展的製藥業以及旨在解決當地流行疾病的基因研究的激增所驅動,這是一個充滿活力的市場。中國處於領先地位,政府對生物技術的大力支持,以及基於 CRISPR 的基因組編輯工具等新型轉染技術的專利數量不斷增加。日本和印度透過再生醫學和疫苗研究也顯示出巨大的市場成長潛力。
FPNV定位矩陣
FPNV定位矩陣對於評估轉染試劑和設備市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對轉染試劑和設備市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.轉染試劑及設備市場規模及預測如何?
2.轉染試劑和設備市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些?
3. 轉染試劑和設備市場的技術趨勢和法規結構是什麼?
4.轉染試劑及設備市場主要廠商的市場佔有率如何?
5. 進入轉染試劑和設備市場的合適型態和策略手段是什麼?
[193 Pages Report] The Transfection Reagents & Equipment Market size was estimated at USD 2.48 billion in 2023 and expected to reach USD 2.79 billion in 2024, at a CAGR 12.76% to reach USD 5.76 billion by 2030.
Transfection reagents & equipment are pivotal in the field of molecular and cellular biology, facilitating the introduction of nucleic acids into cells. This process is essential for research and development in genetics, protein production, and therapeutic drug development. The global market for transfection reagents and equipment is expanding, driven by the growth in biologics production, the rising demand for synthetic genes, and advancements in cell research. Increased research activities in biotherapeutics, along with rising investments in biotechnology and pharmaceutical R&D, are driving market growth. Continuous expansion of the gene therapy sector and the development of novel vaccines are expanding the usage of transfection reagents & equipment. The high cost of transfection reagents and sophisticated equipment and certain limitations in transfection efficiency and survival rates in some cell types hampers the market growth. Technological advancements in transfection methods for higher efficiency and lower cytotoxicity and the rising development of novel, low-toxicity transfection reagents that can efficiently transfect a wide range of cell types are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.48 billion |
Estimated Year [2024] | USD 2.79 billion |
Forecast Year [2030] | USD 5.76 billion |
CAGR (%) | 12.76% |
Product: Growing usage of transfection reagents to facilitate or enhance the delivery of genetic materials
Transfection equipment plays a pivotal role in delivering genetic material into cells. This segment typically includes electroporators, bioreactors, and other physical or mechanical systems designed to facilitate the efficient and controlled introduction of nucleic acids into cells. Reagents are chemicals or formulations used in transfection procedures to facilitate or enhance the delivery of genetic material into cells. Common types include lipid-based, calcium phosphate, and viral vectors, each offering distinct advantages depending on the transfection target. Different experimental setups require specific types of equipment. Electroporation systems are preferred for their high-efficiency transfection of difficult-to-transfect cell lines and primary cells, while bioreactors offer an advantage in large-scale transfections for therapeutic manufacturing. Lipid-based reagents are widely used for their versatility and ease of use across a broad range of cell types, whereas calcium phosphate is cost-effective for transfecting adherent cells in high-throughput applications.
End User: High potential of transfection reagents & equipment across pharmaceutical & biotechnology companies for the development of vaccines and gene therapies
Academic & research institutes primarily focus on the advancement of scientific research in various fields, including genetics, molecular biology, and biochemistry. For these institutions, transfection reagents and equipment are crucial for experimental and research purposes, particularly in gene expression studies, cloning, and protein production. They often prefer cost-effective, reliable, and easy-to-use solutions that can yield high-efficiency transfection rates without compromising cell viability. Safety and reproducibility are also key considerations. For pharmaceutical & biotechnology companies, transfection technologies are instrumental in drug discovery, therapeutic research, and the development of vaccines and gene therapies. These entities prioritize high-throughput capabilities, scalability, and precision. The focus is on obtaining consistent and reproducible results that can expedite the R&D process and lead to successful commercial applications. Regulatory compliance and scalability for clinical trials are additional critical factors.
Regional Insights
In the Americas, the need for transfection reagents & equipment is driven by a strong emphasis on research and development in the biotechnology and pharmaceutical sectors. Customers in these regions prioritize quality and efficiency, seeking out the latest high-throughput transfection technologies to accelerate drug discovery and genetic research processes. Investments in personalized medicine and gene therapy projects are substantial, aiming to cater to the increasing consumer need for tailored healthcare solutions. European Union (EU) countries stand out for their regulatory leadership in genetic research and strict quality standards for transfection experiments. This has fostered a market environment where collaboration between academic institutions and the biotech industry flourishes, driving forward the development of innovative transfection technologies. The Middle East & Africa show a growing interest in transfection technologies, mainly due to the increasing investment in healthcare and education sectors. The Asia-Pacific region, including China, Japan, and India, presents a dynamic and rapidly expanding market for transfection reagents & equipment market with massive investment in biotechnology research, a burgeoning pharmaceutical industry, and a surge in genetic studies aimed at addressing prevalent local diseases. China is at the forefront, with significant government backing for biotech initiatives and a growing number of patents related to novel transfection techniques, such as CRISPR-based genome editing tools. Japan and India also show substantial market growth potential, driven by research in regenerative medicine and vaccines.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Transfection Reagents & Equipment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Transfection Reagents & Equipment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Transfection Reagents & Equipment Market, highlighting leading vendors and their innovative profiles. These include Active Motif, Inc., Agilent Technologies, Inc., Altogen Biosystems, Applied Biological Materials Inc., Bex Co., Ltd., Bio-Rad Laboratories, Inc., BioVision, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Fugent, LLC, GeneCopoeia, Inc., IBA Lifesciences GmbH, Lonza Group Ltd., MaxCyte, Inc., Merck KGaA, Mirus Bio LLC, Omega Bio-tek, Inc., OriGene Technologies Inc., PerkinElmer, Inc., Polyplus-Transfection SA by Sartorius AG, Promega Corporation, Qiagen N.V., Sartorius AG, SBS Genetech Co., Ltd., Sutter Instrument Co., Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and TransGen Biotech Co., Ltd..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Transfection Reagents & Equipment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Transfection Reagents & Equipment Market?
3. What are the technology trends and regulatory frameworks in the Transfection Reagents & Equipment Market?
4. What is the market share of the leading vendors in the Transfection Reagents & Equipment Market?
5. Which modes and strategic moves are suitable for entering the Transfection Reagents & Equipment Market?